IMIDOMICS
IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an innovative leader in discovery and application of biomarkers and new targets to monitor and cure IMIDs, we create value through the combination of the world's largest IMID biobank, extensive relevant clinical expertise, high-throughput genomic and genetic analysis, and intellectual property. IMIDomics is located at Vall d'Hebron Hospital in Barcelona, Spain and on the HudsonAlpha Institute campus in Huntsville, Alabama.
IMIDOMICS
Industry:
Biotechnology Health Care
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Website Url:
http://www.imidomics.com
Status:
Active
Total Funding:
16.5 M USD
Technology used in webpage:
SPF Apple Mobile Web Clips Icon Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS PHP ReCAPTCHA V2 CPanel SSL
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
TARIS Biomedical
TARIS Biomedical is a pharmaceutical company developing therapies for genitourinary system issues.
Current Employees Featured
Founder
Investors List
Evotec
Evotec investment in Corporate Round - IMIDomics
DNS Capital
DNS Capital investment in Series A - IMIDomics
Tao Capital Partners
Tao Capital Partners investment in Series A - IMIDomics
Bristol Myers Squibb
Bristol Myers Squibb investment in Series A - IMIDomics
The Pritzker Organization
The Pritzker Organization investment in Series A - IMIDomics
Official Site Inspections
http://www.imidomics.com
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "IMIDomics"
About - IMIDomics
Jon Gallo, MSc has been a Laboratory Technician at the Translational Immunology Research Lab at IMIDomics since February 2025. In this role, he manages and processes biological samples, performs cell culture, single-cell, …See details»
IMIDomics - Crunchbase Company Profile & Funding
IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an innovative leader in discovery and application of …See details»
Science - IMIDomics
IMIDomics is an emerging global enterprise which combines exclusive access to data with biological insights that will lead to the discovery, targeting, and development of medicines for immune-mediated inflammatory diseases. …See details»
IMIDomics, Inc. Company Profile | San Rafael, CA | Competitors ...
Find company research, competitor information, contact details & financial data for IMIDomics, Inc. of San Rafael, CA. Get the latest business insights from Dun & Bradstreet.See details»
IMIDomics - Org chart - The Org
Explore IMIDomics' organizational chart. Discover current team members including executives, board members, and advisors.See details»
IMIDomics 2025 Company Profile: Valuation, Funding …
IMIDomics General Information Description. Developer of analytical software designed for treating patients with immune-mediated inflammatory diseases. The company's analytics platform extracts unique insights from disease biology …See details»
IMIDomics - Contacts, Employees, Board Members, Advisors
Organization. IMIDomics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Contacts 5. About. IMIDomics has 7 current employee …See details»
IMIDomics - Overview, News & Competitors | ZoomInfo.com
IMIDomics, Inc. is a privately held global biotechnology company focused on the discovery and development of new medicines for the treatment of immune-mediated inflammatory diseases …See details»
IMIDomics | VHIR - Vall d'Hebron Institut de Recerca
IMIDomics was founded in 2013 with the aim of finding therapeutic and diagnostic solutions for immune-mediated inflammatory ... The Pritzker Organization and TAO Capital, among other …See details»
IMIDomics Company Profile - Office Locations, Competitors ... - Craft
IMIDomics is a company that develops medicine diagnostics and therapeutics to optimize treatment of IMID (immune-mediated inflammatory diseases) patients. It utilizes a platform that …See details»
IMIDomics
Dr. Craves is the Executive Chairman and CEO of IMIDomics and has been involved in the company since it was founded. He was formerly the Founder of Bay City Capital life science …See details»
Imidomics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Imidomics, Inc. with its drug pipeline, therapeutic area, technology platform, 15 news, and 3 literature, Disease Domain:Immune System Diseases, Technology Platform:Monoclonal …See details»
IMIDomics - Funding, Financials, Valuation & Investors - Crunchbase
IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. ... How much …See details»
IMIDomics - Products, Competitors, Financials, Employees, …
IMIDomics focuses on discovering and developing medicines for immune-mediated inflammatory diseases (IMIDs). Use the CB Insights Platform to explore IMIDomics's full profile. IMIDomics - …See details»
Contact - IMIDomics
IMIDomics Inc. 1000 4th Street, Suite 500 San Rafael, CA 94901, USA. IMIDomics Establecimiento Permanente España. Parc Científic de Barcelona Edifici Cluster II, Planta 3, …See details»
IMIDomics™ Closes $16.5 Million Series A Financing to Advance …
Jul 27, 2021 The round was led by DNS Capital with additional investment from Bristol Myers Squibb, The Pritzker Organization, Tao Capital and others. IMIDomics was founded in 2015, following a decade of incubation within Vall d’Hebron Hospital in Barcelona, during which the IMID-Biobank was built. The company relocated to the United States in 2021.See details»
IMIDomics emerges with $16.5M, former Takeda exec at the helm, …
Jul 27, 2021 After 15 years of laying the groundwork, IMIDomics is coming out of the shadows with $16.5 million and a mission to bring precision medicine to inflammatory ailments such as …See details»
UCB announces strategic investment in IMIDomics, Inc to advance ...
Brussels (Belgium), and San Rafeal, CA (US), 4 th March, 2024 (18:00 CET) – UCB (Euronext, Brussels: UCB), a global biopharmaceutical company, today announced a strategic equity …See details»
IMIDomics - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 28, 2025 IMIDomics has raised a total funding of $16.5M over 4 rounds. Its first funding round was on Jan 01, 2020. Its latest funding round was a Series A round on Mar 04, 2024 for …See details»
Pipeline - IMIDomics
IMIDomics is an emerging global enterprise which combines exclusive access to data with biological insights that will lead to the discovery, targeting, and development of medicines for …See details»